PlainPill

GHK-Cu vs TB-500 for pain & inflammation

Short answer: For pain & inflammation, more users report improvement with GHK-Cu — 89% of 28 reports, versus 84% of 168 for TB-500.

GHK-Cu has 0 meta-analyses and 1 randomized trials on PubMed; TB-500 has 0 and 3.

Based on 457 reports about GHK-Cu and 652 about TB-500. Not medical advice.

GHK-Cu
Peptide
TB-500
Peptide
User score5449
Verdict
Mostly positive
Mostly positive
Positive
of reports that state an outcome
62%67%
Reports457652
ResearchCResearch: LimitedCResearch: Limited
Meta-analyses / RCTs0 / 10 / 3
Mainly used for
Weight loss
% reporting improvement
88% (8)100% (8)
Appetite
% reporting improvement
—100% (2)
Focus
% reporting improvement
75% (4)50% (2)
Energy
% reporting improvement
—50% (4)
Sleep
% reporting improvement
80% (5)60% (5)
Anxiety
% reporting improvement
50% (4)29% (7)
Mood
% reporting improvement
86% (7)89% (9)
Performance
% reporting improvement
100% (5)100% (17)
Recovery
% reporting improvement
95% (21)97% (208)
Pain & inflammation
% reporting improvement
89% (28)84% (168)
Digestion
% reporting improvement
100% (4)100% (2)
Heart & lipids
% reporting improvement
33% (3)60% (5)
Skin & hair
% reporting improvement
87% (193)84% (19)
Immunity
% reporting improvement
100% (4)60% (5)
Longevity
% reporting improvement
100% (2)—
Common side effectsinjection site, redness, stinging, injection painanxiety, fatigue, dizziness, allergic reaction
Typical dose reportedNot listedNot listed
GHK-Cu
What a user said
“Love it. 44 F. Totally helped even out my skin tone (Irish red cheeks), reduced wrinkles on my forehead and neck, thickened my hair which had been thinning, and grew my eye lashes.”
Full GHK-Cu profile →
TB-500
What a user said
“They reduce neuroinflammation in the brain caused by either head injuries or drug abuse. Ive used them both for this and it works.”
Full TB-500 profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate